DK0462210T3 - Vacciner mod ikke-typebestemmelige Haemophilus influenzae - Google Patents

Vacciner mod ikke-typebestemmelige Haemophilus influenzae

Info

Publication number
DK0462210T3
DK0462210T3 DK90905112.0T DK90905112T DK0462210T3 DK 0462210 T3 DK0462210 T3 DK 0462210T3 DK 90905112 T DK90905112 T DK 90905112T DK 0462210 T3 DK0462210 T3 DK 0462210T3
Authority
DK
Denmark
Prior art keywords
determinable
vaccines
extracting
haemophilus influenzae
influenzae
Prior art date
Application number
DK90905112.0T
Other languages
English (en)
Inventor
Gary W Zlotnick
Bruce A Green
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0462210T3 publication Critical patent/DK0462210T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90905112.0T 1989-03-09 1990-03-09 Vacciner mod ikke-typebestemmelige Haemophilus influenzae DK0462210T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (1)

Publication Number Publication Date
DK0462210T3 true DK0462210T3 (da) 1994-10-10

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90905112.0T DK0462210T3 (da) 1989-03-09 1990-03-09 Vacciner mod ikke-typebestemmelige Haemophilus influenzae
DK94100492T DK0606921T3 (da) 1989-03-09 1990-03-09 Fremgangsmåde til isolering af Haemophilus influenzae protein E

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94100492T DK0606921T3 (da) 1989-03-09 1990-03-09 Fremgangsmåde til isolering af Haemophilus influenzae protein E

Country Status (13)

Country Link
US (4) US5601831A (da)
EP (2) EP0462210B1 (da)
JP (1) JP2955014B2 (da)
KR (1) KR100188323B1 (da)
AT (2) ATE195076T1 (da)
AU (1) AU648251B2 (da)
CA (1) CA2047681C (da)
DE (2) DE69033600T2 (da)
DK (2) DK0462210T3 (da)
ES (2) ES2150450T3 (da)
FI (1) FI914241A7 (da)
NO (1) NO913518L (da)
WO (1) WO1990010458A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CN1511519A (zh) * 1997-11-12 2004-07-14 - 2型t辅助细胞介导的免疫病的治疗
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
BR0011817B1 (pt) 1999-06-25 2011-11-01 processos para extrair proteìnas de membrana interna, para extrair proteìnas de membrana externa, para extrair proteìna p4 de membrana externa recombinante lipiadada (rp4), e, para extrair proteìna p6 de membrana externa recombinante lipidada (rp6).
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
WO2001013948A1 (en) * 1999-08-20 2001-03-01 The General Hospital Corporation Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CA2418036A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
CA2446355A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
IL159209A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
AU2002310760A1 (en) * 2001-06-12 2002-12-23 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA04008890A (es) * 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
ES2557160T3 (es) * 2006-10-23 2016-01-22 Nestec S.A. Modulación del aroma y el sabor mediante biotransformación en productos lácteos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5442641B2 (ja) * 2009-01-07 2014-03-12 大塚製薬株式会社 全インフルエンザ菌の測定方法
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) * 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
JPS62502262A (ja) * 1985-03-27 1987-09-03 ブロンコスタット・プロプライアタリー・リミテツド アジユバントを含有しないワクチン
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
JP2955014B2 (ja) 1999-10-04
ATE110965T1 (de) 1994-09-15
DK0606921T3 (da) 2000-09-04
JPH07508972A (ja) 1995-10-05
WO1990010458A1 (en) 1990-09-20
DE69012318D1 (de) 1994-10-13
US5601831A (en) 1997-02-11
US5780601A (en) 1998-07-14
ATE195076T1 (de) 2000-08-15
EP0606921A1 (en) 1994-07-20
NO913518D0 (no) 1991-09-06
EP0606921B1 (en) 2000-08-02
FI914241A0 (fi) 1991-09-09
DE69012318T2 (de) 1995-03-09
KR100188323B1 (ko) 1999-06-01
ES2150450T3 (es) 2000-12-01
CA2047681C (en) 2000-02-01
US6420134B1 (en) 2002-07-16
EP0462210A1 (en) 1991-12-27
AU5332690A (en) 1990-10-09
ES2063965T3 (es) 1995-01-16
CA2047681A1 (en) 1990-09-10
FI914241A7 (fi) 1991-09-09
DE69033600T2 (de) 2001-04-05
NO913518L (no) 1991-10-29
EP0462210B1 (en) 1994-09-07
AU648251B2 (en) 1994-04-21
US5955580A (en) 1999-09-21
DE69033600D1 (de) 2000-09-07

Similar Documents

Publication Publication Date Title
NO913518D0 (no) Vaksiner for ikke typebestembar haemophilus influenzae.
CA2069450A1 (fr) Procede de fabrication d'un materiau pour osteoplastie a partir d'un tissu osseux naturel et materiau obtenu par ce procede
YU83786A (en) Process for obtaining hypoglicemic thiazolidindione
NO871333L (no) Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
CA2005291A1 (en) Feline infectious peritonitis virus diagnostic tools
EP0272040A3 (en) Thermodynamically-stable aqueous perfluorocarbon microemulsion useful as blood gas control or calibrator
DK694687D0 (da) Hidtil ukendte oligosaccharider, immunogener og vacciner og fremgangsmaader til fremstilling af disseoligosaccharider, immunogener og vacciner
PH25587A (en) Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus
MY103362A (en) Production of proteins in active forms
JPS5359018A (en) Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
NO870834D0 (no) Glysero-3(2)-fosfo-l-serinderivater og salter derav, fremgangsmaater for fremstilling derav og farmasoeytiske preparater inneholdende derivatene.
NZ235297A (en) Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution
YU48589A (en) Process for improved preparation of4,4'-dinitro-stilbene-2,2'-disulphonic acid and it's salts
HU892532D0 (en) Process for producing synthetic peptones and veterinary preparatives containing these compounds
DK44487D0 (da) 1-oe3-(2-hydroxy-3-alkylaminopropoxy)-2-thienylaa-3-phenyl-1-propanon eller syreadditionssalt deraf samt fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende en saadan forbindelse
AU5581186A (en) Protein absorption enhancing agent
ATE53999T1 (de) Verfahren zur herstellung von hexaalkyldisilan.
ATE7267T1 (de) Impfstoff und verfahren zu seiner herstellung.
DE3676429D1 (de) Natriumsalz von etodolsaeure und verfahren zur herstellung.
PT86745A (pt) Process for preparing oxime ethers of 2,6-dioxabicyclo ]3.3.o" octanones
DK401088A (da) Cephalosporinforbindelse, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende den
PT82373A (en) Process for preparing a klebsiella capsular polysaccharide vaccine
IT8622750A0 (it) Procedimento per la preparazione di idrolizzati proteici enzimatici solubili in ambiente acido ed idrolizzati cosi' ottenuti.
ATE63061T1 (de) Verfahren zur herstellung eines stabilen nicorandilpraeparats.